These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 26823493)

  • 1. Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.
    Chen B; Trang V; Lee A; Williams NS; Wilson AN; Epstein EH; Tang JY; Kim J
    Mol Cancer Ther; 2016 May; 15(5):866-76. PubMed ID: 26823493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
    Gruber W; Hutzinger M; Elmer DP; Parigger T; Sternberg C; Cegielkowski L; Zaja M; Leban J; Michel S; Hamm S; Vitt D; Aberger F
    Oncotarget; 2016 Feb; 7(6):7134-48. PubMed ID: 26784250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel indole derivative, 2-{3-[1-(benzylsulfonyl)piperidin-4-yl]-2-methyl-1H-indol-1-yl}-1-(pyrrolidin-1-yl)ethenone, suppresses hedgehog signaling and drug-resistant tumor growth.
    Jung JH; Lee H; Jeon J; Lee YJ; Nada H; Kim M; Lee H; Bhattarai D; Lee K; Ko HW
    Arch Pharm (Weinheim); 2024 Oct; 357(10):e2400218. PubMed ID: 38963677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
    Tian N; Wu H; Zhang H; Yang D; Lv L; Yang Z; Zhang T; Quan D; Zhou L; Xie Y; Xu Y; Wei N; Zhang J; Chen M; Schmitz JC; Tian Y; Wu S
    Bioorg Med Chem; 2020 Aug; 28(16):115584. PubMed ID: 32690258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth.
    Kim J; Tang JY; Gong R; Kim J; Lee JJ; Clemons KV; Chong CR; Chang KS; Fereshteh M; Gardner D; Reya T; Liu JO; Epstein EH; Stevens DA; Beachy PA
    Cancer Cell; 2010 Apr; 17(4):388-99. PubMed ID: 20385363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
    Danhof R; Lewis K; Brown M
    Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance.
    Gruber W; Peer E; Elmer DP; Sternberg C; Tesanovic S; Del Burgo P; Coni S; Canettieri G; Neureiter D; Bartz R; Kohlhof H; Vitt D; Aberger F
    Int J Cancer; 2018 Mar; 142(5):968-975. PubMed ID: 29055107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma.
    Filocamo G; Brunetti M; Colaceci F; Sasso R; Tanori M; Pasquali E; Alfonsi R; Mancuso M; Saran A; Lahm A; Di Marcotullio L; Steinkühler C; Pazzaglia S
    Mol Cancer Ther; 2016 Jun; 15(6):1177-89. PubMed ID: 26960983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recovery of taste organs and sensory function after severe loss from Hedgehog/Smoothened inhibition with cancer drug sonidegib.
    Kumari A; Ermilov AN; Grachtchouk M; Dlugosz AA; Allen BL; Bradley RM; Mistretta CM
    Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10369-E10378. PubMed ID: 29133390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABT-199 inhibits Hedgehog pathway by acting as a competitive inhibitor of oxysterol, rather as a BH3 mimetic.
    Wang J; Zhang Y; Huang WJ; Yang J; Tang WG; Huang TM; Tan WF
    Acta Pharmacol Sin; 2021 Jun; 42(6):1005-1013. PubMed ID: 32855528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors.
    Teske KA; Dash RC; Morel SR; Chau LQ; Wechsler-Reya RJ; Hadden MK
    Eur J Med Chem; 2019 Feb; 163():320-332. PubMed ID: 30529635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression profile of sonic hedgehog signaling-related molecules in basal cell carcinoma.
    Kim HS; Kim YS; Lee C; Shin MS; Kim JW; Jang BG
    PLoS One; 2019; 14(11):e0225511. PubMed ID: 31756206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumoral effects of calcitriol in basal cell carcinomas involve inhibition of hedgehog signaling and induction of vitamin D receptor signaling and differentiation.
    Uhmann A; Niemann H; Lammering B; Henkel C; Hess I; Nitzki F; Fritsch A; Prüfer N; Rosenberger A; Dullin C; Schraepler A; Reifenberger J; Schweyer S; Pietsch T; Strutz F; Schulz-Schaeffer W; Hahn H
    Mol Cancer Ther; 2011 Nov; 10(11):2179-88. PubMed ID: 21878656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A sterol analog inhibits hedgehog pathway by blocking cholesterylation of smoothened.
    Liu YB; He LM; Sun M; Luo WJ; Lin ZC; Qiu ZP; Zhang YL; Hu A; Luo J; Qiu WW; Song BL
    Cell Chem Biol; 2024 Jul; 31(7):1264-1276.e7. PubMed ID: 38442710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the Smoothened inhibitor, IPI-926, on smoothened ciliary localization and Hedgehog pathway activity.
    Peluso MO; Campbell VT; Harari JA; Tibbitts TT; Proctor JL; Whitebread N; Conley JM; White KF; Kutok JL; Read MA; McGovern K; Faia KL
    PLoS One; 2014; 9(3):e90534. PubMed ID: 24608250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
    Li QR; Zhao H; Zhang XS; Lang H; Yu K
    Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triazoles bind the C-terminal domain of SMO: Illustration by docking and molecular dynamics simulations the binding between SMO and triazoles.
    Liu M; Liang G; Zheng H; Zheng N; Ge H; Liu W
    Life Sci; 2019 Jan; 217():222-228. PubMed ID: 30543826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.
    Galimberti F; Busch AM; Chinyengetere F; Ma T; Sekula D; Memoli VA; Dragnev KH; Liu F; Johnson KC; Guo Y; Freemantle SJ; Andrew AS; Greninger P; Robbins DJ; Settleman J; Benes C; Dmitrovsky E
    Int J Oncol; 2012 Nov; 41(5):1751-61. PubMed ID: 22923130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Mechanism for Activation of GLI1 by Nuclear SMO That Escapes Anti-SMO Inhibitors.
    Rahman MM; Hazan A; Selway JL; Herath DS; Harwood CA; Pirzado MS; Atkar R; Kelsell DP; Linton KJ; Philpott MP; Neill GW
    Cancer Res; 2018 May; 78(10):2577-2588. PubMed ID: 29463581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.